Table 1 Clinical features of patients with paraneoplastic cerebellar degeneration and non‐small‐cell lung cancer.
| Patient | Age (years)/ sex | Time to cancer diagnosis (months) | Rankin score | CSF pleocytosis | Treatment | Outcome |
|---|---|---|---|---|---|---|
| 1 | 47/M | 2.5 | 4 | Yes | Chemotherapy | Death from cancer, progression of PCD |
| 2 | 54/M | 1 | 3 | Yes | Chemotherapy, radiotherapy | Death from myocardial infarction 6 months later, PCD: complete recovery |
| 3 | 73/M | 30 | 3 | No | None | Death from cancer, PCD: progression |
| 4 | 65/M | 2 | 3 | No | Chemotherapy, radiotherapy | Lost to follow‐up |
| 5 | 52/M | 7 | 3 | No | Surgery, chemotherapy | Tumour in remission, PCD: stable |
| 6 | 63/M | 2 | 3 | No | Surgery, chemotherapy | Death from cancer, PCD: remission, then relapse at the time of tumour progression |
| 7 | 62/F | 3 | 4 | Yes | Chemotherapy | Death from cancer, progression of PCD |
| 8 | 56/F | 6 | 4 | Yes | Chemotherapy, radiotherapy | Tumour in remission, PCD: stable |
| 9 | 66/M | 3 | 4 | No | Surgery | Tumour in remission, PCD: partial improvement (Rankin score 2), stable for 18 months |
CSF, cerebrospinal fluid; F, female; M, male; PCD, paraneoplastic cerebellar degeneration.